If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

  • There is currently no data for BMK

Directorate Change

6 Nov 2017 07:00

RNS Number : 5754V
Benchmark Holdings PLC
06 November 2017
 

 

Benchmark Holdings plc

("Benchmark", the "Company" or the "Group")

 

Appointment of Non-Executive Directors

 

Benchmark strengthens the board bringing in leading industry and commercial expertise

 

Benchmark, the aquaculture biotechnology and food chain sustainability business, announces the appointment of Hugo Wahnish and Yngve Myhre as Non-Executive Directors of the Company with immediate effect.

 

Hugo Wahnish (65) has over 35 years of experience in the animal health and pharmaceuticals industry, firstly with GlaxoSmithKline, and more recently with Merck during a period of major growth in the organisation. Hugo held the post of Chief Commercial Officer Animal Health at Merck, having responsibility for Merck's commercial operations worldwide. Since stepping down from that role in 2012, Hugo has acted as an independent senior advisor with several multinational companies, private equity groups and consulting firms primarily in the animal health sector. Hugo brings a wealth of international experience to the board of Benchmark, alongside his expertise in aggressively growing businesses and in the commercialisation of medicines and animal health products. Hugo is based in the United States.

 

Yngve Myhre (48) has more than 20 years experience in the aquaculture sector as a senior executive, adviser and investor. Yngve was chief executive of leading Norwegian salmon producer Salmar, and of international white fish supplier Aker Seafood during periods of successful growth. He is now chairman of Chilean salmon producer Nova Austral, recently acquired by Cargill, and sits on the boards of Mediterranean fish producer Andromeda and Norwegian aquaculture research institute Nofima. Yngve also acts as strategic adviser to investors in the aquaculture sector. Yngve has a very strong track record in Benchmark's focus area of aquaculture, both in the Norwegian and international markets. Yngve is based in Norway.

 

Information in respect of Hugo Wahnish and Yngve Myhre, as required by Rule 17 and Schedule 2(g) of the AIM Rules for Companies, is set out below.

 

Benchmark's Chairman, Alex Hambro, commented:

 

"We are delighted to welcome Hugo and Yngve to the Board of Benchmark. Their combined expertise and experience in the aquaculture and pharmaceutical industries will broaden the Board of Benchmark as the Company seeks to maximise value from its unique portfolio of products and technologies.

 

 The Board of Benchmark carried out an extensive international search to bring to the Board additional leading international industry and commercialisation expertise. Attracting Hugo and Yngve is a testament of the strength of our industry standing, our technology platform and our potential."

 

 

Additional information:

 

Neither Hugo Wahnish nor Yngve Myhre hold any shares in the Company.

 

 

Hugo Wahnish's current directorships/partnerships:

 

Dinicola PartnersMaxima LLC

 

Yngve Myhre's current directorships/partnerships:

 

Rosøy AS

Nova Austral SA

Nova Austral Management Invest AS

Blåfjell AS

Blåfjell Holding

Aqua Site AS

Aqua Site Holding

Perseus Seafood LimitedHelgeland Adventure AS

 

Yngve Myhre's past directorships/partnerships (last 5 years):

 

SalMar ASA

Albain Midco Norway AS (EWOS Group)

Arnarlax and Kvitholmen AS

Trænafestivalen

 

There is no further information to be disclosed pursuant to AIM Rule 17 and Schedule 2(g) of the AIM Rules for Companies.

 

- Ends -

 

 For further information, please contact:

 

Benchmark Holdings plc Tel: 020 7920 3150

Malcolm Pye, CEO

Ivonne Cantu, Investor Relations Director

Rachel Aninakwah, Communications

 

Numis Tel: 020 7260 1000

Michael Meade / Freddie Barnfield (NOMAD)

James Black (Corporate Broking)

 

Tavistock Tel: 020 7920 3150

Sophie Praill

 

 

Notes to Editors:

 

Benchmark challenges the status quo in aquaculture.

 

Since 2000, Benchmark has consistently worked to build a platform to serve its customers, helping food producers take control of their biological environment through the combination of genetics, nutrition, health and knowledge services. Through its in-depth knowledge of animal biology Benchmark is able to tackle the key issues facing producers primarily in the aquaculture sector.

 

The Company has proven distribution capabilities in high growth markets and operates internationally with R&D facilities, commercial farms, diagnostic laboratories, manufacturing sites, production facilities and commercial offices across 27 countries in five continents. As at 30 September 2017, Benchmark employed 952 people.

 

For further information on Benchmark please visit www.benchmarkplc.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOABLBDBIXGBGRX
Date   Source Headline
28th Feb 20257:00 amRNSQ1 Results
11th Feb 20257:00 amRNSNotice of AGM
7th Feb 202511:05 amRNSNotice of Q1 Results
31st Jan 20257:00 amRNSTotal Voting Rights
7th Jan 20257:00 amRNSPublication of Annual Report
31st Dec 20247:00 amRNSTotal Voting Rights
16th Dec 20241:00 pmRNSResult of General Meeting
12th Dec 20247:01 amRNSChairman Appointment
12th Dec 20247:01 amRNSQ4 Results
12th Dec 20247:00 amRNSFull Year Results
29th Nov 202411:30 amRNSTotal Voting Rights
27th Nov 20249:12 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
26th Nov 20243:00 pmRNSNotice of GM
26th Nov 202412:56 pmGNWForm 8.3 - [BENCHMARK HOLDINGS PLC - 25 11 2024] - (CGAML)
26th Nov 202411:15 amRNSForm 8.3 - Benchmark Holdings plc
26th Nov 20249:39 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
25th Nov 20249:54 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
25th Nov 20247:00 amRNSNotice of Q4 and Full Year Results
25th Nov 20247:00 amRNSDisposal of the Genetics Business
22nd Nov 20249:22 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
22nd Nov 20247:00 amRNSForm 8.3 - Benchmark Holdings plc
21st Nov 202410:15 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
21st Nov 20247:00 amRNSForm 8.3 - Benchmark Holdings plc
20th Nov 20249:53 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
15th Nov 20249:21 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
14th Nov 20249:18 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
13th Nov 20249:48 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
12th Nov 20249:39 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
12th Nov 20247:00 amRNSForm 8.3 - Benchmark Holdings Plc
7th Nov 20249:27 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
6th Nov 20249:25 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
5th Nov 202410:00 amRNSRule 2.9 Announcement
5th Nov 20249:21 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
31st Oct 20249:57 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
31st Oct 20247:00 amRNSTotal Voting Rights
30th Oct 202411:08 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
29th Oct 20249:54 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
28th Oct 20249:50 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
25th Oct 202410:34 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
24th Oct 202411:21 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
23rd Oct 202410:33 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
22nd Oct 202411:43 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
22nd Oct 202410:07 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
21st Oct 202411:02 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
18th Oct 202410:21 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
17th Oct 20249:59 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
11th Oct 202410:51 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
10th Oct 202410:13 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
9th Oct 202410:38 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
7th Oct 202411:41 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.